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Abstract — It is possible to advocate that, as far as complex-
ity is concerned, the medical devices sector is comparable to 
the aviation and nuclear industries. Some of the arguments 
used are the broad definition of the term “medical device”, the 
multiplicity of regulations and the nature of the relation be-
tween manufacturers and users. In such environment, the 
uncertainty associated to the development of novel devices is 
high and justifies the use of dedicated methodologies. In gen-
eral, the application of product development methodologies 
helps to reduce the duration of the tasks, optimize the available 
resources and obtain products and/or services that please 
customers. In the case of medical devices, the authors believe 
that resorting to such methodologies is crucial to overcome the 
industry’s complexity without losing competitiveness. The 
product development process involves the following steps: 
identification of an opportunity, voice of the customer, concept 
development, design, test and validation and launch. This 
paper describes each one of the aforementioned stages and 
suggests adaptations to the healthcare sector. 
Keywords— Product development, Optimization, Decision, 
Review, Public health regulation and supervision 
I. INTRODUCTION  
According to the World Health Organization (WHO), 
there are around 1.5 million different medical devices [1]. 
At first glance, this number is overwhelming but, consider-
ing that the term “medical device” includes apparatuses 
ranging from simple tongue depressors to drug-eluting 
stents or engineered tissues, the figure seems reasonable. 
The definition of “medical device” is one of the features 
that makes this sector complex. Other aspects are the multi-
plicity of regulations that medical devices have to comply 
with and the existence of motley agencies that evaluate 
devices before commercialization. The characteristics that 
make the medical device’s industry complex are detailed in 
this paper. In addition, it presents the traditional approach to 
product development and the authors show how a dedicated 
methodology can contribute to the reduction of costs during 
the development of new products while increasing the de-
vice’s acceptance by its users, i.e., the actual use of the 
device / service. 
II. MATERIALS AND METHODS 
In recent years, the number of publications regarding 
product development methodologies has increased. Howev-
er, few are dedicated to medical devices. Thus, the infor-
mation presented here was retrieved not only from books 
and scientific journals but also from web pages of govern-
ments and agencies responsible for protecting and promot-
ing public health through regulation and supervision. 
Data from the WHO indicates the European Union (EU) 
and US as responsible for more than 50% of the manufac-
ture of medical devices [2]. In this work, only the regula-
tions and agencies from these countries are considered. 
III. RESULTS 
A. Definition and classification of medical devices 
As a general rule, the expression “medical device” refers 
to any apparatus, software, material or other similar or re-
lated article, intended to be used in the diagnosis, preven-
tion, monitoring, treatment or alleviation of a disease or an 
injury. In the US, the definition appears in section 201(h) of 
the “Food Drug & Cosmetic Act”, while in Europe, it is 
given by the “Medical Devices Directive 93/42/EEC”. 
Medical devices can be categorized as preventive, diag-
nostic, therapeutic and assistive, according to the stage of 
health care in which they are used. It is also possible to 
distinguish between medical devices for general use (e.g. 
thermometer, stethoscope) and disease-specific. However, 
this categorization is merely organizational. The classifica-
tion, on the other hand, defines the medical device’s path to 
market.  
The classification of medical devices in done according 
to a series of factors, including the risk it poses to both user 
and operator in case of failure and the time it is intended to 
be in continuous use. The US defined three classes while 
EU defined four (Table 1). 
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In the US, medical devices are regulated by the Center 
for Devices and Radiological Health (CDRH) of the FDA 
(Food and Drug Administration). Although, this govern-
mental agency uses third parties for the preliminary assess-
ment of low- and medium-risk devices, it retains final au-
thority over all devices’ approval. In EU, the pre-market 
review and approval is conducted by independent third-
party testing laboratories, named notified bodies, accredited 
by Member State Health Ministries. 
Table 1 Medical device classification and requirements for market 
clearance in the US and EU 
System Class Examples 
Requirements for market 
clearance 
US 
I 
Adhesive bandages 
Hospital beds 
General controls 
II 
Blood pressure cuffs 
Sutures 
General Controls and Special 
Controls 
III 
Pacemaker 
Vascular graft 
General Controls and Pre-
market Approval (PMA) 
EU 
I 
Surgical gauze 
Wheelchairs 
Self-certifiable 
CE marking 
IIa 
Hearing aids 
Ultrasound equipment 
Assessment by a Notified 
Body 
CE marking 
IIb 
Infusion pumps 
Surgical lasers 
III 
Prosthetic joints 
Stent-grafts 
B. Path to market 
A medical device to be commercialized in EU has to pre-
sent a CE mark. In order to obtain it, the manufacturer has 
to demonstrate and document compliance with the regula-
tions and issue a declaration of conformity. In certain situa-
tions, such as class I sterile devices, it may be required the 
intervention of a Notified Body, which, in general, is a 
profit-driven organization and charges fees for its services. 
Class III devices require clinical studies, except when data 
already exists. The evaluation process may take between 
three days to several months depending on the class of the 
device, the size of the manufacturer, the size of the technical 
file and the duration of the clinical study. 
In the US, the CDRH is responsible for the pre-market 
assessment of new medical devices. Low risk (class I) de-
vices are subject to certain general controls, such as re-
quirements for labeling and good manufacturing practices. 
Most of them are not required to undergo the pre-market 
clearance through the 510(k) process, i.e., a 90-day review 
process based on the argument that the device is equivalent 
to one that was already approved by the FDA. Class II de-
vices, in addition to general controls, have to comply with 
special controls, namely performance standards, guidance 
documents or implementation of post-market surveillance. 
Class III medical devices are subject to Premarket Approval 
Application (PMA), the most stringent evaluation. This 
process can take between 6 months to 2 years, depending on 
factors such as the report of clinical studies and quality of 
documents. The Human Device Exemption (HDE) is a 
specific path for class III medical devices designed to ad-
dress diseases and conditions that affect fewer than 4000 
patients / year. 
C. Post- market surveillance 
Since medical devices involve human safety, manufac-
turers have two obligations when they deliver a device to 
the market: post-market surveillance and adverse event 
reporting. The first allows the detection of rare but serious 
adverse events and long-term failures that are unable to 
detect during the pre-market surveillance due to the short 
duration of the clinical studies and / or the limited number 
of participants. 
The data gathered during this period is important to mon-
itor the device’s safety and effectiveness. Furthermore, it 
helps determining if the device merits coverage from gov-
ernments and / or reimbursement agencies and assessing the 
effectiveness and cost-effectiveness beyond that required 
for entering the market. 
In order to issue alerts or recalls for unsafe or ineffective 
items, manufacturers are also obliged to keep trace of the 
devices sold. 
D. Medical device’s market 
In the last decade, the medical device’s global market has 
been steadily growing; in 2009, it was estimated in more 
than $222 billion USD [3] and it is expected to worth more 
than $289 billion USD by 2011 [4]. This growth can be 
explained by an increase of the global healthcare demand 
and by the aging of the population and the evolution of 
illnesses from acute and infectious types towards chronic 
ones. 
The development of medical devices is technologically 
intensive. A typical company starts as a university spin-off 
relying in a single device or technology, to only then grow 
to a diversified organization [5]. In this sector, mergers and 
strategic alliances are quite common because they represent 
quick and effective ways of manufacturers to gain new 
product lines and technologies and enter new markets. 
Besides the clinical and non-clinical studies medical de-
vices are subjected before entering the market to demon-
strate quality, safety, and efficacy, proofs of cost-
effectiveness are required. This evaluation is important 
since it creates expectations regarding the quality of the 
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medical care and the efficacy of the treatment. In addition, 
national healthcare services and insurances systems use the 
result to decide if coverage is provided. Coverage and reim-
bursement decisions impact directly on the manufacturers’ 
attainable revenues. 
As medical devices are highly substitutable by similar 
products with superior efficacy, profits depend on new 
solutions which compel manufacturers to be constantly 
innovating, researching and presenting new solutions. 
E. Medical device’s users 
Medical device users are extremely heterogeneous. For 
example, doctors, nurses and patients can be quoted as only 
few within the myriad of possible users. Besides the variety, 
each group has a distinctive perspective given the fact the 
device is used differently and with dissimilar expectations 
by each of them. Furthermore, the passage and sales method 
differs from the ones used by other industries. 
In their work, Shah et al [6] presented a definition and a 
classification for medical device’s users (Fig.1). The au-
thors distinguish medical device user from end-user. The 
first refers to ‘a person who uses a medical device for the 
treatment and/or care of him‐ /her‐self or someone else’, 
while the second refers to ‘a person who is the ultimate 
beneficiary of the usage of a medical device and who can 
also be the user of a medical device if using the medical 
device for him‐ /her‐self’. 
 
Fig. 1 Medical device users (adapted from [6]) 
F. Product development 
Product development refers to the process of creating 
products with new or different characteristics to offer fresh 
or additional features to customers. While some authors 
describe this process with only 5 steps, others name as 
many as 25 stages [7]. 
Normally, the development of a product is triggered by a 
need or an idea. Then, the design team identifies the specific 
problems that customers intend to solve purchasing a good 
or service (customer needs) and generate concepts. From 
the panoply of concepts, only one is developed and opti-
mized. Following this, prototypes and/or small series are 
produced. These pre-series are evaluated by a restrict num-
ber of clients or by certifier companies. The process ends 
with the launch of the product in the market. 
In spite of the design process being commonly represent-
ed in a linear fashion (as shown in Fig 2), the development 
of a product is an iterative process in which different steps 
can be performed simultaneously. 
IV. DISCUSSION 
Although the differences regarding medical device’s def-
inition and classification appear to be subtle, they affect 
how devices enter the market and even the company’s strat-
egy. For example, some US companies have branches in 
Europe because the approval process is faster and the data 
gathered can be used in the FDA’s approval process. Other 
companies seek a certain classification for their devices so 
they can either be introduced faster in the market or force 
competition to go through time consuming clinical studies. 
However, this may change in the future since, in 1992, a 
Global Harmonization Task Force (GHTF) was formed with 
the goal to achieve greater uniformity between national 
medical device regulatory systems. 
The definition of medical devices leads to an assorted 
and broad range of products with a wide diversity in risk 
and variable development time as well as variable produc-
tion quantities. All this adds to the particularity that medical 
devices are sold, after the approval process finishes, primar-
ily to entities that are not the end-user. Moreover, since 
medical devices are bought according to hospitals or gov-
ernments politics, it becomes difficult, if not impossible, to 
use the same market strategies commonly used for other 
products. In this context, metrics such return on investment 
or units sold are inappropriate to measure a company’s 
success. 
As stated earlier, a typical medical device company relies 
in a single product or technology. Considering that post-
market surveillance is expensive and affects how companies 
are seen in the market and their products are accepted, the 
cost of failure can be very high. In order to survive, compa-
nies cannot afford a mistake and a methodic approach can 
ensure that every detail is addressed. Furthermore, such an 
approach is essential to comply with the regulations regard-
ing quality. 
As populations demand better health products and ser-
vices, hospitals and governments struggle with rising costs 
and actively search technological innovations. Companies 
that are able to offer cheaper solutions will take the lead. A 
dedicated product development methodology will help to 
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understand all the stakeholders’ point of view and reduce 
development costs. 
Several tools and strategies have been proposed to make 
product development more efficient. However, there is little 
evidence regarding their utility in the medical device sector 
[8]. The authors commonly believe that this can change if 
an appropriate nomenclature is adopted highlighting the 
importance of each step in the development of a novel de-
vice. 
Fig. 2 depicts the different steps in the development of a 
medical device.  
 
Fig. 2 Different steps of the medical device’s development process 
The identification of the customer is crucial; it is im-
portant to understand who will select the device and what 
arguments will be used to make a decision. 
The voice of customer is the step in which the needs are 
gathered. In this stage, designers will have to consider the 
devices’ learning curve and “wear the user’s shoes”, that is, 
they will have to understand the user’s limitations and de-
sires. 
Concept selection is another crucial step because from 
this point onward, the design team is committed to a con-
cept whose modification implies delays and additional 
costs. The decision made at this point should consider that 
the introduction of a sophisticated technology does not 
guarantee high-quality patient care. It should also consider 
the diseases incidence, the class the device will have, uncer-
tainties (during the development a new treatment can be-
come available) and should guarantee that complies with the 
inspection process. 
After the design of the device, the next steps are the clin-
ical and non-clinical studies and the approval process. Spe-
cial attention must be given to these steps because, unlike 
drugs, there is no placebo for medical devices. Furthermore, 
final appraisals cannot be generalized across health systems 
because they depend on local values, disease incidence, 
costs and resources. 
After the device is launched, the post-market surveillance 
needs to be considered. 
V. CONCLUSIONS 
The medical device industry has unique features: product 
diversification, high uncertainty regarding research, high 
technological complexity, high likelihood of market closure 
and high threshold for product inspection. These character-
istics justify the adoption of a dedicated approach. 
The adoption of a dedicated methodology could contrib-
ute to reduce development costs, increase the devices ac-
ceptance, improve the device’s safety and efficiency and 
reduce device recalls. This would improve the company’s 
image and assist to obtain funds for further researches. 
In spite of the advantages mentioned, data shows that 
methodologies are more widespread in academics rather 
than in manufacturers. Thus, an adequate methodology for 
the development of medical devices should be developed in 
a partnership with industry. 
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